# US 2025/0034096 A1 · Compounds and methods for the targeted degradation of androgen receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0034096 A1
- Document ID: US20250034096A1
- Status: Published application
- Kind: A1
- Application number: 18/772,066
- Filed: 2024-07-12
- Published: 2025-01-30
- Earliest claimed: 2016-10-11
- Assignees: Arvinas Operations, Inc.
- Applicants: Arvinas Operations, Inc.
- Inventors: Michael BERLIN; Andrew P. CREW; Craig M. CREWS; Hanqing DONG; Keith R. HORNBERGER; Lawrence B. SNYDER; Jing WANG; Kurt ZIMMERMANN
- Web page: https://patentgrep.com/patent/US20250034096A1

## CPC

- C07D 233/42: Sulfur atoms
- A61K 31/02: Halogenated hydrocarbons
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/497: containing further heterocyclic rings
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 13/08: of the prostate
- A61P 35/00: Antineoplastic agents
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 209/48: with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C07D 211/76: attached in position 2 or 6
- C07D 213/72: Nitrogen atoms (nitro radicals C07D213/61)
- C07D 221/20: Spiro-condensed ring systems
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 237/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 239/24: having three or more double bonds between ring members or between ring members and non-ring members
- C07D 241/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

## Claims

### Claim at position 1

-34. (canceled)

### Claim 35

A compound represented by the structure:
ABM-L-CLM,
or a pharmaceutically acceptable salt thereof, wherein:
(a) ABM is:
wherein:
W1 is aryl optionally substituted by 1 or more halogen; hydroxyl; NO2; CN; C1-6 alkyl optionally substituted by 1 or more halogen or C1-6 alkoxyl; or C1-6 alkoxyl optionally substituted by 1 or more halogen;
each Y3 is independently O, NRY2, CRY1RY2, or C═O;
Q is a 4-membered alicyclic-substituted with 0-6 RQ;
each RQ is independently halogen; C1-6 alkoxy; or C1-6 alkyl optionally substituted by 1 or more halogen or C1-6 alkoxyl;
RY1 and RY2 are each, independently, H, halogen, C1-6 alkoxy, or C1-6 alkyl optionally substituted by 1 or more halogen or C1-6 alkoxyl;
W2 is heteroaryl optionally substituted by 1-4 RW2;
each RW2 is, independently, halogen; C1-6 alkyl optionally substituted by 1 or more F; OH; NRY1RY2; CN; or OC1-3alkyl optionally substituted by 1 or more F; and
is the point of attachment of the ABM to the chemical linker group (L);
(b) L is a chemical linker group that is covalently bound to the ABM and the CLM, and has the chemical structure -(AL)q-, wherein:
q is an integer greater than or equal to 1;
each AL is selected from CRL1RL2, O, S, NRL3, CO, CRL1═CRL2, C≡C, C3-11 cycloalkyl optionally substituted with 1-6 RL1, C5-13 spirocycloalkyl optionally substituted with 1-9 RL1, C3-11 heterocyclyl optionally substituted with 1-6 RL1, C5-13 spiroheterocycloalkyl optionally substituted with 1-8 RL1, aryl optionally substituted with 1-4 RL1, and heteroaryl optionally substituted with 1-4 RL1; and
RL1, RL2, and RL3 are each, independently, H, halogen, C1-8alkyl, OC1-8alkyl, NHC1-8alkyl, N(C1-8alkyl)2, C3-11cycloalkyl, aryl, heteroaryl, C3-11heterocyclyl, OC3-8cycloalkyl, NHC3-8cycloalkyl, N(C3-8cycloalkyl)2, N(C3-8cycloalkyl)(C1-8alkyl), OH, NH2, COC1-8alkyl, CO2H, CN, CF3, CHF2, CH2F, NO2, CONHC1-8alkyl, or CON(C1-8alkyl)2, or RL1 and RL2 are linked to form a cycloalkyl or a heterocyclyl moiety; and
(c) CLM is:
wherein:
W is CH2 or C═O;
A is H;
n is an integer from 1 to 4;
wherein when n is 1, R is OR′ covalently joined to the linker group (L); and when n is 2, 3, or 4, one R is OR′ covalently joined to the linker group (L) and the remaining R are selected from C1-6 alkyl, Cl, F, Br, I, CF3, CN, and OCF3;
R′ is cycloalkyl, aryl, heteroaryl, and heterocyclyl; and
represents a bond that may be stereospecific ((R) or (S)) or non-stereospecific.

### Claim 36 (depends on 35)

The compound of claim 35, or a pharmaceutically acceptable salt thereof, wherein ABM is:
wherein:
W1 is
R22 is H or CN;
each R23 is independently halogen or CF3;
Y3, Y4, and Y5 are each independently O, NRY2, CRY1RY2, or C═O;
each RY1 and RY2 is H or C1-6 alkyl;
R1 and R2 are each independently H or methyl;
W2 is heteroaryl optionally substituted by 1, 2, or 3 RW2; and
each RW2 is independently halogen; C1-6 alkyl optionally substituted by 1 or more F; or O—C1-3alkyl optionally substituted by 1 or more F.

### Claim 37 (depends on 36)

The compound of claim 36, or a pharmaceutically acceptable salt thereof, wherein each R1 and R2 is methyl.

### Claim 38 (depends on 35)

The compound of claim 35, or a pharmaceutically acceptable salt thereof, wherein W1 is:

### Claim 39 (depends on 38)

The compound of claim 38, or a pharmaceutically acceptable salt thereof, wherein W1 is:

### Claim 40 (depends on 39)

The compound of claim 39, or a pharmaceutically acceptable salt thereof, wherein W1 is

### Claim 41 (depends on 35)

The compound of claim 35, or a pharmaceutically acceptable salt thereof, wherein W2 is pyrrolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, imidazolyl, triazolyl, triazinyl, tetrazolyl, indolyl, isoindolyl, indolizinyl, azaindolizinyl, furanyl, isoxazolyl, or oxazolyl.

### Claim 42 (depends on 41)

The compound of claim 41, or a pharmaceutically acceptable salt thereof, wherein W2 is pyrrolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyrazolyl, imidazolyl, triazolyl, triazinyl, tetrazolyl, indolyl, isoindolyl, indolizinyl, azaindolizinyl, furanyl, isoxazolyl, or oxazolyl.

### Claim 43 (depends on 42)

The compound of claim 42, or a pharmaceutically acceptable salt thereof, wherein W2 is pyrimidinyl.

### Claim 44 (depends on 35)

The compound of claim 35, or a pharmaceutically acceptable salt thereof, W1 is
and W2 is pyrimidinyl.

### Claim 45 (depends on 35)

The compound of claim 35, or a pharmaceutically acceptable salt thereof, wherein R′ is cycloalkyl covalently joined to the linker group (L).

### Claim 46 (depends on 45)

The compound of claim 45, or a pharmaceutically acceptable salt thereof, wherein R′ is cyclobutyl covalently joined to the linker group (L).

### Claim 47 (depends on 35)

The compound of claim 35, or a pharmaceutically acceptable salt thereof, wherein n is 1; and R is OR′, wherein R′ is cycloalkyl covalently joined to the linker group (L).

### Claim 48 (depends on 47)

The compound of claim 47, or a pharmaceutically acceptable salt thereof, wherein n is 1; and R is OR′, wherein R′ is cyclobutyl covalently joined to the linker group (L).

### Claim 49 (depends on 35)

The compound of claim 35, or a pharmaceutically acceptable salt thereof, wherein n is 2; one R is OR′, wherein R′ is cycloalkyl covalently joined to the linker group (L); and the other R is F.

### Claim 50 (depends on 49)

The compound of claim 49, or a pharmaceutically acceptable salt thereof, wherein n is 2; one R is OR′, wherein R′ is cyclobutyl covalently joined to the linker group (L); and the other R is F.

### Claim 51 (depends on 35)

The compound of claim 35, or a pharmaceutically acceptable salt thereof, wherein each AL is selected from CRL1RL2, NRL3, and C3-11 heterocyclyl optionally substituted with 1-6 RL1.

### Claim 52 (depends on 51)

The compound of claim 51, or a pharmaceutically acceptable salt thereof, wherein each AL is selected from CH2, NRL3, piperazinyl, and piperidinyl.

### Claim 53 (depends on 51)

The compound of claim 51, or a pharmaceutically acceptable salt thereof, wherein each AL is selected from CH2, NRL3, and piperidinyl.

### Claim 54 (depends on 53)

The compound of claim 53, or a pharmaceutically acceptable salt thereof, wherein RL3 is H, methyl, ethyl, or iso-propyl.

### Claim 55 (depends on 53)

The compound of claim 53, or a pharmaceutically acceptable salt thereof, wherein RL3 is iso-propyl.

### Claim 56 (depends on 35)

A pharmaceutical composition comprising the compound of claim 35, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
